A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors

Inclusion criteria

• Subjects with ability to understand and voluntarily agree to participate by giving written informed consent form for the study.
• Patients with unresectable recurrent or metastatic solid tumors.
• There is at least one lesion that could be measured.
• An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1.
• Adequate organ functions as defined.
• Life expectancy ≥ 3 months.

Exclusion criteria

• Patients with known active central nervous system (CNS) metastases.
• Subjects with other malignancy in five years before the first dose.
• Patients with tumor-related pain that cannot be controlled as determined.
• Patients with serious cardiovascular and cerebrovascular diseases.
• Uncontrollable third-space effusion, such as pleural effusion, pericardial effusion or peritoneal effusion.
• Patients with severe infections.
• History of immunodeficiency.
• History of autoimmune diseases.
• Active infection.
• Pregnant or nursing women.
• Known history of serious allergic reactions to the investigational product or its main ingredients.